Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19
Status:
Recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
The IMPACT-SIRIO 5 is a randomized, double-blind, phase III clinical trial aimed to evaluate
safety and efficacy of PCSK9 inhibition on clinical outcome in patients during the
inflammatory stage of the COVID-19. During the hospitalization participants will be
randomized in a 1:1 ratio to either receive PCSK9 inhibitor (evolocumab) or to receive
placebo (saline solution). Furthermore, all people included in the study will be treated in
accordance to the latest recommendations on the treatment of patients infected with
SARS-CoV-2.